Raykov Rosty's Form 4 filing
Fennec Pharmaceuticals Inc.FENC · filed Nov 4, 2024
- Accession no.
- 0001415889-24-026039
- Filed
- Nov 4, 2024
- Trade date
- Oct 31-Nov 4, 2024
- Filing delay
- 4 days
- Rule 10b5-1 plan
- Checked
This filing lists 2 non-derivative transactions. Open-market sales total $10.5K. It was filed 4 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Raykov RostyCIK 0001468316 | Director |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Oct 31, 2024 | Common shares | AGrant or awardAcquired | +2,431 | $0.00 | $0 | 68,863 | Direct | |
| Nov 4, 2024 | Common shares | SSaleDisposed | −2,431 | $4.31 | −$10,477.61 | 66,432 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
No transaction price on this filing refers to a footnote.